Skip to content

FAQs

 

Dr. Roger S. Newton, the co-discoverer and product champion for Lipitor, founded the second Esperion in 2008 after re-acquiring from Pfizer the name and program along with worldwide patent rights to bempedoic acid.  The Company was incorporated in the State of Delaware in 2008.

Esperion shares of stock were available for purchase publically in June 2013.

Shares of Esperion common stock are listed on the NASDAQ Global Market under the ticker symbol ESPR.

Esperion’s corporate headquarters are located in Ann Arbor, MI.

Computershare
250 Royall Street
Canton, MA 02021
Phone: 312-360-5195

All notifications of change and/or inquiries regarding stock certificates should be sent to the transfer agent at:
Computershare
250 Royall Street
Canton, MA 02021
Phone: 312-360-5195

Esperion does not offer a direct stock purchase plan.  Shares of Company stock should be purchased through a broker.

Esperion’s fiscal year is based on the calendar year.  First quarter ends on March 31st.  Second quarter ends June 30th.  Third quarter ends September 30th.  Fourth quarter ends December 31st.

Esperion does not currently pay a dividend.

Esperion’s auditors are Ernst and Young.

Please send inquiries by email to ir@esperion.com, or contact Esperion IR by phone at 734-887-3903.

Bempedoic acid (ETC-1002) was discovered and patented by the original Esperion team. We re-acquired full worldwide rights to bempedoic acid from Pfizer in May 2008 when Pfizer announced they were exiting cardiovascular research and development. Bempedoic acid composition of matter (COM) patent coverage, including patent term extension (PTE), extends through 2030 in the U.S and through 2028 in Europe and Japan. Additionally, post-approval market exclusively may also be available in certain territories. Patent coverage for the fixed dose combination of bempedoic acid and ezetimibe (BA+EZ) is in prosecution worldwide.

Esperion is passionately committed to developing and commercializing complementary, oral therapies for patients and physicians globally that could potentially significantly reduce elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia inadequately treated with current lipid-modifying therapies. Bempedoic acid, Esperion-discovered and developed, brings a targeted mechanism of action to the space that could potentially address unmet medical needs in a way that is “patient-friendly, physician-friendly, and payer-friendly”.

Please submit your question using the form below.

Contact Form
* Indicates required field
http://apps.shareholder.com/captcha/captcha.aspx?verifyid=1773131983&CompanyID=AMDA-1UZG66&t=.jpg